Radar›Companies›Laboratory Analytical Instruments Stocks in USA: Revenue Cohort 2
United States laboratory analytical instruments industry landscape illustrating listed-company operations, infrastructure and market activity
Prism Finance USA · comparison snapshot

Laboratory Analytical Instruments Stocks in USA: Revenue Cohort 2

A five-company laboratory analytical instruments cohort selected by latest filing revenue, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 04 September 2026Not investment adviceRanked by Prism readiness
Readiness leaderEyePoint Pharmaceuticals · 39
Strongest available pathBioForce Nanosciences · +320.7%
Widest latest marginScientific Industries · -24.1%
Companies compared5 · U.S.-listed
01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1EYPT · Nasdaq

EyePoint Pharmaceuticals

A U.S.-listed issuer classified by the SEC in Laboratory Analytical Instruments

Founded 1987Wilmington$394.9M market cap
View full Companies Radar profile
39Cautious
Snapshot price$4.58as of page date
Monthly-close return-56.0%five-year window
FY2025 revenue$0.03BEyePoint, Inc.
Net margin-739.4%FY2025
P/E snapshot-1.7xone ratio, not a verdict
Prism attention9.1%share across these five
Filing track recordRevenue, USD billions
-15.1%
$0$0.0B$0.0B$0.0BFY2021: $0.037BFY2022: $0.041BFY2023: $0.046BFY2024: $0.043BFY2025: $0.031B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -4.0%
52-week position4% through range
$3.95$19.11
News mentions899
Community mentions0partial coverage
U.S.-scope patents182
Prism Insights

What sits behind the readiness signal

Observed risk 2/100higher means more observed risk
Earnings signal26/100
Management stability90/100
Market position3/100
Capital-event signal71/100
Innovation pulse10/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 0 asset-acquisition events and 9 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 7 company announcements in that window.

Recent risk watch

Recent available records contain 1 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2LAB · Nasdaq

Fluidigm

A U.S.-listed issuer classified by the SEC in Laboratory Analytical Instruments

Founded 1999San Francisco, California$269.1M market cap
View full Companies Radar profile
38Cautious
Snapshot price$0.69as of page date
Monthly-close return-89.5%five-year window
FY2025 revenue$0.09BSTANDARD BIOTOOLS INC.
Net margin-87.8%FY2025
Prism attention17.8%share across these five
Filing track recordRevenue, USD billions
-34.7%
$0$0.1B$0.1B$0.2BFY2021: $0.131BFY2022: $0.098BFY2023: $0.106BFY2024: $0.174BFY2025: $0.085B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -10.1%
52-week position6% through range
$0.63$1.72
News mentions1.8K
Community mentions0partial coverage
U.S.-scope patents650
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal39/100
Management stability90/100
Market position0/100
Capital-event signal55/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3BFNH · OTC

BioForce Nanosciences

A U.S.-listed issuer classified by the SEC in Laboratory Analytical Instruments

Founded 1999Ames, Iowa$204.6M market cap
View full Companies Radar profile
33Cautious
Snapshot price$6.10as of page date
Monthly-close return+320.7%five-year window
FY2020 revenue$0.00BBIOFORCE NANOSCIENCES HOLDINGS, INC.
Net margin-891187.4%FY2020
Prism attention0.3%share across these five
Filing track recordRevenue, USD billions
+9.0%
$0$0.0B$0.0B$0.0BFY2018: $0.000BFY2019: $0.000BFY2020: $0.000B201820192020
FY2018–FY2020 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 4.4%
52-week position99% through range
$0.18$6.16
News mentions30
Community mentions0partial coverage
U.S.-scope patents34
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal55/100
Management stability90/100
Market position0/100
Capital-event signal0/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4SCND · OTC

Scientific Industries

A U.S.-listed issuer classified by the SEC in Laboratory Analytical Instruments

Founded 1954Bohemia, New York$9.5M market cap
View full Companies Radar profile
31Cautious
Snapshot price$0.80as of page date
Monthly-close return-86.1%five-year window
FY2025 revenue$0.01BSCIENTIFIC INDUSTRIES INC
Net margin-24.1%FY2025
Prism attention1.4%share across these five
Filing track recordRevenue, USD billions
-48.3%
$0$0.0B$0.0B$0.0BFY2020: $0.010BFY2022: $0.011BFY2023: $0.011BFY2024: $0.011BFY2025: $0.005B20202022202320242025
FY2020–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -15.2%
52-week position91% through range
$0.30$0.85
News mentions138
Community mentions0partial coverage
U.S.-scope patents132
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal32/100
Management stability90/100
Market position9/100
Capital-event signal15/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 3 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5SEER · Nasdaq

Seer

A U.S.-listed issuer classified by the SEC in Laboratory Analytical Instruments

Founded 2004Charleston, South Carolina$108.0M market cap
View full Companies Radar profile
26Avoid
Snapshot price$1.95as of page date
Monthly-close return-94.4%five-year window
FY2025 revenue$0.02BSeer, Inc.
Net margin-444.0%FY2025
P/E snapshot-1.9xone ratio, not a verdict
Prism attention71.4%share across these five
Filing track recordRevenue, USD billions
+150.5%
$0$0.0B$0.0B$0.0BFY2021: $0.007BFY2022: $0.015BFY2023: $0.017BFY2024: $0.014BFY2025: $0.017B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 25.8%
52-week position47% through range
$1.55$2.41
News mentions7.1K
Community mentions0partial coverage
U.S.-scope patents602
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal40/100
Management stability70/100
Market position0/100
Capital-event signal0/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

BioForce Nanosciences
+320.7%
EyePoint Pharmaceuticals
-56.0%
Scientific Industries
-86.1%
Fluidigm
-89.5%
Seer
-94.4%

Latest revenue

USD billions, official filing scope shown on each company card.

Fluidigm
$0.09B
EyePoint Pharmaceuticals
$0.03B
Seer
$0.02B
Scientific Industries
$0.01B
BioForce Nanosciences
$0.00B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Scientific Industries
-24.1%
Fluidigm
-87.8%
Seer
-444.0%
EyePoint Pharmaceuticals
-739.4%
BioForce Nanosciences
-891187.4%

Prism news attention

Normalized share across these five names; attention is not quality.

Seer
71.4%
Fluidigm
17.8%
EyePoint Pharmaceuticals
9.1%
Scientific Industries
1.4%
BioForce Nanosciences
0.3%
03 · Prism readout

What the signals say—and what they do not

The headline share is normalized laboratory analytical instruments news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Seer leads the conversation

It holds 71.4% of measured laboratory analytical instruments news attention and also carries the basket's largest revenue base at $0.02B.

Price path

BioForce Nanosciences leads the available price paths

Its monthly-close return is +320.7% for the five-year window. At the other end, Seer is -94.4% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Scientific Industries has the widest latest margin

Its FY2025 net margin is -24.1%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Seer shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -1.9x while its five-year window price return is -94.4%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · EYPT

EyePoint Pharmaceuticals

899available Prism news records

Prism top themes

Price action & investor response
40
Capital allocation & transactions
31
Earnings & financial performance
24
Legal, arbitration & regulatory
13
Leadership & governance
7

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-23.9%124 latest 12m vs 163 prior 12m
2024-01: 16 mentions2024-02: 12 mentions2024-03: 18 mentions2024-04: 12 mentions2024-05: 23 mentions2024-06: 7 mentions2024-07: 6 mentions2024-08: 11 mentions2024-09: 6 mentions2024-10: 18 mentions2024-11: 8 mentions2024-12: 6 mentions2025-01: 8 mentions2025-02: 48 mentions2025-03: 15 mentions2025-04: 10 mentions2025-05: 19 mentions2025-06: 8 mentions2025-07: 4 mentions2025-08: 10 mentions2025-09: 2 mentions2025-10: 16 mentions2025-11: 20 mentions2025-12: 8 mentions2026-01: 9 mentions2026-02: 10 mentions2026-03: 15 mentions2026-04: 16 mentions2026-05: 13 mentions2026-06: 1 mentions2024-012026-06

Machine-classified coverage tone

95.0% positive+3.1 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 17generic drug approval 16stock price 13share price 12phase ii efficacy studies 8phase iii trial 7investment deal 6phase iv trial 6

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-20–2026-06-03 · trend and themes shown through 2026-06
Areas of research · LAB

Fluidigm

1,766available Prism news records

Prism top themes

Earnings & financial performance
36
Capital allocation & transactions
35
Leadership & governance
27
Price action & investor response
22
Legal, arbitration & regulatory
9

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-1.2%245 latest 12m vs 248 prior 12m
2023-12: 0 mentions2024-01: 27 mentions2024-02: 32 mentions2024-03: 21 mentions2024-04: 13 mentions2024-05: 33 mentions2024-06: 19 mentions2024-07: 16 mentions2024-08: 31 mentions2024-09: 9 mentions2024-10: 9 mentions2024-11: 8 mentions2024-12: 6 mentions2025-01: 23 mentions2025-02: 74 mentions2025-03: 16 mentions2025-04: 12 mentions2025-05: 25 mentions2025-06: 27 mentions2025-07: 32 mentions2025-08: 17 mentions2025-09: 23 mentions2025-10: 17 mentions2025-11: 17 mentions2025-12: 14 mentions2026-01: 27 mentions2026-02: 24 mentions2026-03: 10 mentions2026-04: 24 mentions2026-05: 13 mentions2023-122026-05

Machine-classified coverage tone

90.8% positive-5.9 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

biomarker discovery 18pharmacogenomics 18stem cell banking 16diagnostic biotechnology 15quarterly results 9genetic profiling 9earnings report 8cancer biomarkers 7

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-06–2026-05-11 · trend and themes shown through 2026-05
Areas of research · SEER

Seer

7,079available Prism news records

Prism top themes

Leadership & governance
22
Earnings & financial performance
16
Capital allocation & transactions
10

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-35.8%704 latest 12m vs 1,096 prior 12m
2024-02: 83 mentions2024-03: 66 mentions2024-04: 52 mentions2024-05: 47 mentions2024-06: 75 mentions2024-07: 59 mentions2024-08: 70 mentions2024-09: 50 mentions2024-10: 65 mentions2024-11: 61 mentions2024-12: 70 mentions2025-01: 184 mentions2025-02: 298 mentions2025-03: 79 mentions2025-04: 54 mentions2025-05: 51 mentions2025-06: 60 mentions2025-07: 54 mentions2025-08: 63 mentions2025-09: 73 mentions2025-10: 71 mentions2025-11: 54 mentions2025-12: 58 mentions2026-01: 58 mentions2026-02: 88 mentions2026-03: 70 mentions2026-04: 106 mentions2026-05: 57 mentions2026-06: 5 mentions2026-07: 1 mentions2024-022026-07

Machine-classified coverage tone

79.1% positive-0.8 pp vs preceding four quarters
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

biomarker discovery 25minority health outcomes 19cancer biomarkers 15contemplative prayer 13patent litigation 12high-efficiency air conditioner 10energy saving ac 10low energy hvac 9

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-07-31 · trend and themes shown through 2026-07
05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

EYPT

EyePoint Pharmaceuticals

through 2026-03-21
Company announcements 29Earnings releases 15Leadership changes 9Listing / IPO 3Business contracts 1
  1. Lawsuits

    Pinnacle health stories this week spotlight EyePoint Pharmaceuticals suing Ocular Therapeutix for allegedly spreading misinformation about its eye drug.

  2. Company announcements

    EyePoint Pharmaceuticals (EYPT) just shared that its pivotal Phase 3 trial for DURAVYU in wet age-related macular degeneration has passed the second independent safety committee review.

  3. Earnings releases

    For the second quarter ended June 30, 2025, total net revenue was $5.3 million compared to $9.5 million for the quarter ended June 30, 2024.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

LAB

Fluidigm

through 2025-02-14
Leadership changes 2
  1. Leadership changes

    Richard DeLateur has joined Fluidigm (South San Francisco, California) as CFO.

  2. Leadership changes

    Fluidigm named Gerhard F. Burbach to its board of directors…

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

BFNH

BioForce Nanosciences

through 2025-02-14
Company announcements 1Leadership changes 1
  1. Leadership changes

    Gabor Bethlendy has been named sales manager for BioForce Nanosciences (Ames, Iowa).

  2. Company announcements

    BioForce Nanosciences Inc., of Ames, Iowa, said it will formally close its merger with Silver River Ventures Inc. within the next few weeks, following the Jan. 27 shareholder vote to approve the deal.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

SCND

Scientific Industries

through 2026-03-31
Earnings releases 20Leadership changes 4Asset acquisitions 1
  1. Earnings releases

    Scientific Industries, Inc. (OTCQB:SCND), a developer of digitally simplified bioprocessing solutions and vision-based pill counters, today reported financial results for the fiscal year ended December 31, 2025.

  2. Asset acquisitions

    Scientific Industries Inc. (OTCQB: SCND) (the “Company”) announced that it has sold its Genie Division to Troemner, LLC, a manufacturing sister company of OHAUS Corporation, (the “Buyer”) for $9.6 million in cash less working capital adjustments, plus up to $1.5 million in cash earnout over a twelve-month period.

  3. Leadership changes

    Mr. Marcus Frampton, who recently resigned, as a Class B director.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

SEER

Seer

through 2026-05-13
Earnings releases 14
  1. Earnings releases

    Seer reported Q1 FY2026 revenue of $2.8M in the official-filing series.

  2. Earnings releases

    Seer reported FY2025 revenue of $16.6M in the official-filing series.

  3. Earnings releases

    Seer reported Q3 FY2025 revenue of $4.1M in the official-filing series.

Cached Prism company-event evidence fallback; totals describe available coverage and the displayed highlights prefer filing-backed earnings rows.

07 · Industry landscape

Laboratory Analytical Instruments Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary laboratory analytical instruments news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

analytical laboratory instrument market

2 sources72.9% extraction confidence
2024 extracted base$171.56B
2030 extracted forecast$171.56B
Implied source CAGR7.6%
accelerating investment in biotechgrowing R&D in pharmaceuticalaging population

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Laboratory Analytical Instruments news pulse

7,952available Prism news records
Latest 12m volume+14.8%3473 vs 3024 records
Positive classified tone95.0%+4.2 pp vs prior four quarters
2024-01: 288 mentions2024-02: 334 mentions2024-03: 270 mentions2024-04: 242 mentions2024-05: 321 mentions2024-06: 179 mentions2024-07: 192 mentions2024-08: 184 mentions2024-09: 182 mentions2024-10: 189 mentions2024-11: 244 mentions2024-12: 181 mentions2025-01: 252 mentions2025-02: 473 mentions2025-03: 364 mentions2025-04: 377 mentions2025-05: 207 mentions2025-06: 212 mentions2025-07: 247 mentions2025-08: 303 mentions2025-09: 226 mentions2025-10: 227 mentions2025-11: 366 mentions2025-12: 526 mentions2026-01: 216 mentions2026-02: 377 mentions2026-03: 303 mentions2026-04: 457 mentions2026-05: 13 mentions2024-012026-05
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Available U.S.-primary Prism records matching analytical, instrument, laboratory. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

astronomical instrumentation and telescope design
1,181
surgical instrument accessories
897
art rock experimentation
679
cosmology and large-scale universe structure
634
ophthalmic diagnostic instruments
614
psychedelic rock soundscapes
536

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

genre-defying rock 695conceptual rock albums 636unconventional rock instruments 585avant-garde rock 566narrative-driven rock 517symphonic rock pieces 494mind-expanding rock 484telescope construction 473

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

accelerating investment in biotech

2 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card
Opportunity · demand

astronomical instrumentation and telescope design

1,181 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata
Opportunity · innovation

Innovation and product activity

1,207 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule
Caution · market restraint

reduction in free trade

334 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata
Caution · news pulse

Coverage growth can reverse

+14.8% news volume

The latest 12 months contain 3,473 matched records versus 3,024 in the previous window.

Available Prism coverage through 2026-05-05
Caution · sentiment

Classified tone is not demand

95.0% positive · +4.2pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →
08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 3826 (Laboratory Analytical Instruments), selected as the first five names that pass all live publication gates from the latest filing revenue candidate pool ranked 6–10. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

  • Official annual filingsFY revenue history and latest profitability
  • U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
  • Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
  • Prism market-growth extractionDated third-party Laboratory Analytical Instruments Industry in USA market benchmark with source-count, geography and confidence context
Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 04 September 2026.
09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions
Comparisons
Anomalies

Seer has the widest attention-readiness rank gap

It ranks #1 by measured news attention (71.4%) and #5 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Seer in Companies Radar

Seer shows a price-operating divergence to inspect

Its displayed filing-revenue change is +150.5% while its available monthly-close return is -94.4%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Seer in Companies Radar
Explanations

Attention measures coverage volume, not quality

Seer's 71.4% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Seer in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open EyePoint Pharmaceuticals's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 39/100 score.

Open EyePoint Pharmaceuticals in Companies Radar
Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.
Coming soon